April 20, 2026 · Form 4 insider transaction
Koppel Adam bought 1,562,500 shares of Kailera Therapeutics, Inc. at $16.00 per share, a transaction worth $25.00M. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 0 days after the transaction.
Represents securities held directly by BCLS Fund IV Investments, LP ("BCLS Fund IV Investments").; Dr. Koppel is a Partner of Bain Capital Life Sciences Investors, LLC ("BCLSI"). BCLSI is the ultimate general partner of BCLS Fund IV Investments. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.